Sign in
CompletedNo phase

Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis

Key facts

Who runs it
Changhai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,066 people enrolled
Started
17 Nov 2023
Ended
23 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lactated ringers solution
  • normal saline
Record updated
28 March 2025

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • All patients with chronic pancreatitis aged between18 and 85 years who were eligible for treatment with ESWL for pancreatic stones were eligible for enrolment

Who cannot take part

  • Patients receiving more than 1.5 mL/kg/h or 3 L/24 h of intravenous fluids in the 24 h before ESWL
  • Severe liver disease (cirrhosis, liver abscess)
  • Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP>100pg/ml or Ejection Fraction value<50% should be excluded
  • Hypo- or hypernatremia (serum Na+ levels < 130 or > 150 mmol/L)
  • Respiratory insufficiency (pO2 < 60 mmHg or saturation < 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with Forced Expiratory Volume in the first second (FEV1) <70% are excluded
  • Patients readmitted to the hospital for ESWL during the study period
  • Acute pancreatitis in the last 3 days
  • Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <70 mmHg)
  • Pregnancy
  • Unwilling or unable to provide consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to clarify whether aggressive intravenous hydration with lactated Ringer's solution could reduce the incidence of post-ESWL pancreatitis in patients with chronic pancreatitis.

The 2 groups in the trial

  • Aggressive hydration groupTreatment being tested

    Periprocedural hydration with intravenous 20 mL/kg lactated Ringer's solution within 60 min from the start of ESWL (first shockwave delivered), directly followed by 3 mL/kg per h for 8 h.

    Treatment: Lactated ringers solution

  • Restricted hydration groupExisting treatment, for comparison

    Periprocedural hydration with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).

    Treatment: normal saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis: A Multicenter, Prospective, Randomized Clinical Trial
Record updated
28 March 2025